Begin main content

Open Calls for Patient Input

This page lists Common Drug Review (CDR) drug applications received by CADTH and the deadlines for filing patient group input for each drug. For more information about how to provide input, please visit the CDR Patient Input page

RespiClick (fluticasone propionate / salmeterol xinafoate)

Indications: Asthma

Call For Patient Input: September 5, 2017

Patient Input Closed: October 25, 2017

RespiClick (fluticasone propionate )

Indications: Asthma

Call For Patient Input: September 5, 2017

Patient Input Closed: October 25, 2017

MDK-Nitisinone (nitisinone)

Indications: Hereditary tyrosinemia type 1

Call For Patient Input: August 31, 2017

Patient Input Closed: October 23, 2017

Vemlidy (tenofovir alafenamide fumarate)

Indications: Hepatitis B, chronic

Call For Patient Input: August 30, 2017

Patient Input Closed: October 20, 2017

Ozurdex (dexamethasone )

Indications: Diabetic macular edema

Call For Patient Input: August 25, 2017

Patient Input Closed: October 17, 2017

Revolade (eltrombopag)

Indications: Immune thrombocytopenia purpura, chronic

Call For Patient Input: August 25, 2017

Patient Input Closed: October 17, 2017

Actemra (tocilizumab)

Indications: Giant cell arteritis (GCA)

Call For Patient Input: August 25, 2017

Patient Input Closed: October 17, 2017

Dupixent (dupilumab)

Indications: atopic dermatitis

Call For Patient Input: August 15, 2017

Patient Input Closed: October 4, 2017

TBC (infliximab)

Indications: rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis

Call For Patient Input: August 4, 2017

Patient Input Closed: September 26, 2017